Why Amylyx is pulling ALS drug Relyvrio from US market after study
Release time：2024-05-08 22:06:00 Source：International Identities news portal
WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
- Previous：Boy Scouts of America changes name after 114 years to 'boost inclusion'
- Next：Rep. Greene and Speaker Johnson meet for a second day as possible vote on his ouster simmers
Related articles
- Instacart partners with Uber Eats to offer restaurant deliveries
- Chinese giant pandas meet public in Doha's first Panda House ahead of World Cup
- County in China's Shaanxi transforms ecological resources to green economy
- Total profits of China's SOEs hit $650 billion in 2023
- What to know about the Penske scandal that has rocked IndyCar
- Visa exemption agreement will further enhance Sino
- An epic tale worth telling
- Roundup: Chinese FM Expounds on China
- Brandon Nimmo's 3
- Comicomment: How the American Dream turned into a nightmare?
- Rays starter Ryan Pepiot likely heading to IL after getting hit on left calf by a 107.5 mph liner
- More foreign buyers to participate in Canton Fair as nation expands opening
- Holiday to see pickup in outbound travel
- More foreign buyers to participate in Canton Fair as nation expands opening
- Zendaya's forbidden fruit look divides the Internet! Star's peacock
- Roundup: Chinese FM Expounds on China
- In pics: cultural and tourism services exhibition at CIFTIS
- In pics: cultural and tourism services exhibition at CIFTIS
- 'Samurai sword
- An epic tale worth telling
Random recommendation
- Copyright © 2024 Powered by Why Amylyx is pulling ALS drug Relyvrio from US market after study ,International Identities news portal sitemap